Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.
作者信息
Akenroye Ayobami, Zhou Guohai, Jackson John W, Segal Jodi, Alexander G Caleb, Singh Sonal
机构信息
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Allergy. 2023 Apr;78(4):1116-1119. doi: 10.1111/all.15564. Epub 2022 Nov 5.
Abstract
摘要
相似文献
1
Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.
Allergy. 2023 Apr;78(4):1116-1119. doi: 10.1111/all.15564. Epub 2022 Nov 5.
2
Selection of Biologics in Severe Asthma: A Multifaceted Algorithm.
J Investig Allergol Clin Immunol. 2019;29(4):325-328. doi: 10.18176/jiaci.0398. Epub 2019 Apr 10.
3
Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations.
Allergy. 2022 Sep;77(9):2839-2843. doi: 10.1111/all.15379. Epub 2022 Jun 4.
4
Severe T2-high asthma in the biologics era: European experts' opinion.
Eur Respir Rev. 2019 Jul 8;28(152). doi: 10.1183/16000617.0054-2019. Print 2019 Jun 30.
5
Emerging Biologics in Severe Asthma.
Immunol Allergy Clin North Am. 2016 Aug;36(3):609-23. doi: 10.1016/j.iac.2016.04.001.
6
New perspectives of childhood asthma treatment with biologics.
Pediatr Allergy Immunol. 2019 Mar;30(2):159-171. doi: 10.1111/pai.13007. Epub 2018 Dec 16.
7
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.
Expert Opin Biol Ther. 2022 Jul;22(7):855-870. doi: 10.1080/14712598.2022.2091409. Epub 2022 Jun 23.
8
Biologics for Asthma and Risk of Infection: Cause for Concern?
Immunol Allergy Clin North Am. 2019 Aug;39(3):429-445. doi: 10.1016/j.iac.2019.03.010.
9
Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Expert Rev Clin Immunol. 2020 Mar;16(3):311-319. doi: 10.1080/1744666X.2020.1724089. Epub 2020 Feb 8.
10
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
引用本文的文献
1
Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.
J Allergy Clin Immunol. 2025 May;155(5):1584-1594. doi: 10.1016/j.jaci.2024.10.028. Epub 2024 Nov 7.
2
Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Sci Rep. 2024 May 6;14(1):10404. doi: 10.1038/s41598-024-60864-3.
3
The origins and longevity of IgE responses as indicated by serological and cellular studies in mice and humans.
Allergy. 2023 Dec;78(12):3103-3117. doi: 10.1111/all.15799. Epub 2023 Jul 7.
本文引用的文献
1
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022.
2
Biologic Therapies for Severe Asthma.
N Engl J Med. 2022 Jan 13;386(2):157-171. doi: 10.1056/NEJMra2032506.
3
Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.
Br J Pharmacol. 2014 Feb;171(3):580-94. doi: 10.1111/bph.12362.
4
Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective.
Int J Toxicol. 2001 May-Jun;20(3):149-52. doi: 10.1080/109158101317097728.
Zotero 插件